Risperidone

• 

  Subject Areas on Research

  • A case of infant delirium in the neonatal intensive care unit. 
  • A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder. 
  • An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction. 
  • An unsubstantiated conclusion. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. 
  • Atypical antipsychotics and pituitary neoplasms in the WHO database. 
  • Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. 
  • Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. 
  • Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study. 
  • COMT158 polymorphism and hostility. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. 
  • Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. 
  • Chronic nicotine interactions with clozapine and risperidone and attentional function in rats. 
  • Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. 
  • Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. 
  • Diet and the atypical neuroleptics. 
  • Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. 
  • Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. 
  • Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. 
  • Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. 
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
  • Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. 
  • Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
  • Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. 
  • Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. 
  • Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. 
  • Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. 
  • Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. 
  • Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. 
  • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. 
  • Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. 
  • Efficacy of risperidone on positive features of schizophrenia. 
  • GERI-BD: A Randomized Double-Blind Controlled Trial of Lithium and Divalproex in the Treatment of Mania in Older Patients With Bipolar Disorder. 
  • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. 
  • Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. 
  • Implications of atypical antipsychotic prescribing in the intensive care unit. 
  • Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. 
  • Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. 
  • Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. 
  • Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. 
  • Nicotine-antipsychotic drug interactions and attentional performance in female rats. 
  • Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. 
  • One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. 
  • Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. 
  • Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. 
  • Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 
  • Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine. 
  • Psychopharmacological treatment for very young children: contexts and guidelines. 
  • Psychosis in Parkinson's disease: diagnosis and treatment. 
  • Psychotic disorder in a patient with central and extrapontine myelinolysis. 
  • Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. 
  • Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. 
  • Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 
  • Results of phase 3 of the CATIE schizophrenia trial. 
  • Risks versus benefits of different types of long-acting injectable antipsychotics. 
  • Risperidone and cognitive function in children with disruptive behavior disorders. 
  • Risperidone and explosive aggressive autism. 
  • Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. 
  • Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. 
  • Risperidone-associated diabetes mellitus: a pharmacovigilance study. 
  • Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. 
  • Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. 
  • Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. 
  • Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. 
  • The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. 
  • The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. 
  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 
  • Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. 
  • What CATIE found: results from the schizophrenia trial. 
• 

  Keywords of People

  • Olsen, Maren Karine, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics